Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Alvespimycin IV: Updated Phase I data

Updated data from an ongoing, dose-escalation Phase I trial of alvespimycin plus

Read the full 126 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE